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Abstract
Background: Repetitive transcranial magnetic stimulation of the left temporo-parietal junction area has been studied as a
treatment option for auditory verbal hallucinations. Although the right temporo-parietal junction area has also shown
involvement in the genesis of auditory verbal hallucinations, no studies have used bilateral stimulation. Moreover, little is
known about durability effects. We studied the short and long term effects of 1 Hz treatment of the left temporo-parietal
junction area in schizophrenia patients with persistent auditory verbal hallucinations, compared to sham stimulation, and
added an extra treatment arm of bilateral TPJ area stimulation.
Methods: In this randomized controlled trial, 51 patients diagnosed with schizophrenia and persistent auditory verbal
hallucinations were randomly allocated to treatment of the left or bilateral temporo-parietal junction area or sham
treatment. Patients were treated for six days, twice daily for 20 minutes. Short term efficacy was measured with the Positive
and Negative Syndrome Scale (PANSS), the Auditory Hallucinations Rating Scale (AHRS), and the Positive and Negative
Affect Scale (PANAS). We included follow-up measures with the AHRS and PANAS at four weeks and three months.
Results: The interaction between time and treatment for Hallucination item P3 of the PANSS showed a trend for
significance, caused by a small reduction of scores in the left group. Although self-reported hallucination scores, as
measured with the AHRS and PANAS, decreased significantly during the trial period, there were no differences between the
three treatment groups.
Conclusion: We did not find convincing evidence for the efficacy of left-sided rTMS, compared to sham rTMS. Moreover,
bilateral rTMS was not superior over left rTMS or sham in improving AVH. Optimizing treatment parameters may result in
stronger evidence for the efficacy of rTMS treatment of AVH. Moreover, future research should consider investigating factors
predicting individual response.
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About 50–70% of the patients fulfilling the criteria for
schizophrenia experience auditory verbal hallucinations (AVH)
on a frequent basis [1]. Antipsychotic medication is often chosen
as the first treatment for this disabling symptom of schizophrenia.
However, in 25% of the patients, hallucinations appear to be
refractory to adequate treatment trials with antipsychotic medica-
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tion [2]. The high level of burden accompanied with AVH urges
for the development of more efficient treatments.
Understanding the underlying neural basis of AVH may be
helpful in the development of better treatment options. AVH have
been related to both structural and functional anomalies in frontal,
temporal and parietal regions [3,4]. Furthermore, cingular,
subcortical and cerebellar areas have shown involvement as well
(for an overview, see: [5]). Several theories about the genesis of
AVH have been suggested, but the most popular theory argues
that AVH are a result of misattributions of inner speech to an
external source [6]. Allen et al. [5] postulated a neurocognitive
model in which they state that over-activation of primary and
secondary auditory cortices may be associated with bottom-up
over-perceptualization. Meanwhile, aberrant activation in Broca’s
area (speech production), and reduced connectivity between
Broca’s area and the anterior cingulate (monitoring) and
Wernicke’s area (speech reception), may lead to reduced top-
down control, ultimately resulting in the experience of auditory
verbal hallucinations.
Given the hyperactivation within speech perception areas
during the experience of AVH, it seems plausible that modulation
of the neuronal activity could reduce AVH. The left temporo-
parietal junction area (TPJ) is strongly connected with primary and
secondary auditory cortices, and has therefore been proposed as a
target region for treatment with low frequency repetitive
Transcranial Magnetic Stimulation (rTMS). rTMS constitutes
the administration of brief magnetic pulses with an electro-
magnetic coil on the scalp. Low frequency rTMS can reduce
cortical excitability within the underlying cortical tissue and
connected deeper brain tissues in healthy volunteers [7–9].
Although the exact mechanism of action is not yet understood,
the effect of low frequency rTMS is being explained in terms of
long-term depression (LTD)-like changes in synaptic efficacy [10].
In rats, it has been shown that the inhibiting effect on cortical
excitability endures after multiple rTMS sessions [11]. Researchers
have therefore begun to apply this technique in the treatment of
neurological and psychiatric disorders [12] associated with
aberrant cortical activity. Hoffman et al. [13,14] pioneered this
intervention in schizophrenia patients experiencing AVH. Since
the early 2000’s a number of rTMS trials have been initiated,
aiming to treat AVH, with the majority targeting the left TPJ area
[15–31]. Recent basic cognitive rTMS studies have shown the
relevance of the TPJ area in the language and AVH network [32–
36].
Meta-analytical reviews of the treatment studies have shown
moderate to large effect sizes [37–39]. However, the majority of
these effect sizes are based on the severity of symptoms
immediately after treatment. Little is known about the duration
effects of rTMS for AVH. Only a few studies have been published
on the effects after more than four weeks [16,19,20,28]. From a
clinical perspective, insight into long-term effects of this type of
treatment would be highly advantageous.
Despite neuroimaging findings on the involvement of both the
left and right temporal cortex in the genesis of AVH [3,4], most
treatments have restricted stimulation of low frequency rTMS to
the left TPJ area. This treatment has been found to influence
characteristics like frequency and attentional salience of AVH
[15,16]. The right hemisphere is considered to be dominant for
the processing of emotions [40], especially negative emotions [41].
As AVH are often negative in emotional content [42,43], it is
conceivable that low frequency rTMS treatment over the right
hemisphere down-regulates this negative content.
As an extension of the trial reported by Vercammen et al. [44],
we report on a randomized controlled trial in schizophrenia
patients with 1 Hz rTMS over the left TPJ area, compared to
sham stimulation over the left TPJ area. To investigate whether
stimulation over the right TPJ area would have an additional
effect, we added an extra treatment arm of bilateral TPJ area
stimulation. We included follow-up measures at four weeks and
three months after treatment. We hypothesized that 1 Hz rTMS
over the left TPJ area would result in improvement of AVH,
compared to sham stimulation, and that reduction of AVH would
be further enhanced after bilateral stimulation, compared to both
left TPJ stimulation and sham.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
From July 2006 to March 2012, patients were recruited at
University Medical Center Groningen (UMCG), and collaborat-
ing regional mental health foundations: Lentis, GGz Friesland,
GGz Drenthe and Mediant. All patients met DSM-IV criteria for
schizophrenia; diagnoses were confirmed using Schedules for
Clinical Assessment in Neuropsychiatry [45]. Only patients
reporting frequent (at least daily) medication resistant AVH were
included. Medication resistance was defined as daily occurring
AVH despite at least two adequate trials of antipsychotic
medication for at least four weeks prior to study inclusion.
Medication dose remained unchanged for the duration of the
study. To minimize the risk of inducing seizures by rTMS, patients
with a personal or family history of epileptic seizures were
excluded. Other exclusion criteria were: a history of severe head
trauma or neurological disorder, the presence of intra-cerebral or
pacemaker implants, inner ear prosthesis or other metal prosthet-
ics/implants, severe behavioral disorder, current substance abuse,
and pregnancy.
This study was approved by the licensed local medical ethical
committee of the University Medical Center Groningen (number
2006/052) and conducted in accordance with the latest version of
the Declaration of Helsinki (Protocol S1). As it was not yet
customary in The Netherlands to register non-pharmaceutical
trials when our trial started in 2006, we registered the trial in 2009
in the Dutch trial register when it was advised to do so (www.
trialregister.nl, number: NTR1813). The authors confirm that all
ongoing and related trials for this intervention are registered. Only
patients who were competent to give informed consent were
included. Prior to the study, all subjects gave oral and written
informed consent after the procedure had been fully explained. All
obtained subject data was handled anonymously.
This study was a double-blind randomized controlled trial.
Treatments were given in the University Center of Psychiatry of
the UMCG. Before the start of the trial, envelopes were numbered
sequentially with participant ID numbers. An independent
colleague drew tokens for one of the three treatment conditions,
which were subsequently put into the envelopes. The envelopes
were sealed, and prior to the start of each participant’s treatment
period, the researcher (AV or LB) opened the envelope with the
number that corresponded to the participant’s allocated ID
number. Participant ID numbers were allocated consecutively
based on date of participant intake, which was not controlled by
the TMS administrator. Only the persons who administered the
TMS (either the researchers or a trained nurse) were aware of the
treatment condition. All other people involved – participants,
clinical raters and clinicians – were kept blind. To check for
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blinding success, the participants completed a questionnaire.
Participants were informed about the received treatment when the
last follow-up measurement at three months was completed.
During the trial, patients were either admitted to an inpatient
care unit, a day-hospital, or visited the hospital twice a day.
Demographic and clinical characteristics at baseline are provided
in Table 1.
rTMS procedure
We used a Magstim Rapid System (Magstim Company Ltd,
Whitland, Wales) with a 70 mm figure-of-eight coil. Sham
stimulation was administered using a coil that produced the same
clicking sound, without delivering a measurable magnetic field.
Before the first treatment session, resting motor threshold was only
determined in patients enrolled in an active treatment condition.
The resting motor threshold is defined as the minimum intensity to
induce a noticeable movement of the dominant hand in five out of
ten pulses administered on the contralateral primary motor cortex
[46]. We did not determine the motor threshold in the patients
that were to receive sham treatment, to reduce the risk of
unblinding the participant to the treatment condition, as our sham
procedure produces no physical sensation, but the motor threshold
determination does.
The localization of the TPJ area was based on the 10–20
International System of EEG electrode positions. Both active and
sham stimulation of the left TPJ area were administered halfway
between T3 and P3 electrode positions. In the bilateral condition
the left TPJ area was stimulated for the first 10 minutes of the
session, after which the coil position was switched to the right TPJ
area, halfway between T4 and P4 electrode positions. The 10–20
system has been commonly used in previous rTMS trials for AVH
[16,19–24,26,27,47], because it is a patient-friendly compromise
between time efficiency and individual variability, as it takes
individual head size into account [48].
Treatment was conducted for six consecutive days (except
during the weekends), twice daily, for 20 minutes at 1 Hz on 90%
of resting motor threshold. Patients thus received a total of 14400
pulses during the treatment. There was always a minimum period
of five hours between two treatment sessions.
Power calculation
Previous research using a similar design and rTMS parameters
[22] found significant effects of the treatment on behavioral
variables (Auditory Hallucination Rating Scale). An effect size of
1.22 was observed [22,37]. With the inclusion of 16 subjects in
each treatment arm, and an alpha of ,.05, a power of.90 would
be acquired.
Outcome parameters
All participants were interviewed with the semi-structured
Positive and Negative Syndrome Scale (PANSS) [49] before and
immediately after treatment by two trained raters. For the analyses
we used the scores on hallucination item P3, as well as scores on
the subscales for Positive symptoms, Negative symptoms and
Table 1. Demographic data and baseline characteristics of the sample.
Left TMS (n = 16) Bilateral TMS (n = 15) Sham TMS (n = 16) p
Age (years) Mean (+/2 SD) 37.2 (14.9) 33.9 (9.2) 37.3 (11.6) 0.688
Sex (m/f) N 9/7 8/7 10/6 0.869
Education (years) Mean (+/2 SD) 13.7 (2.0) 13.4 (1.2) 13.7 (2.1) 0.870
Age of onset (years) Mean (+/2 SD) 26.4 (10.2) 23.1 (4.2) 21.8 (6.9) 0.230
Duration of illness (months) Mean (+/2 SD) 150.4 (123.2) 135.8 (123.4) 186.7 (149.4) 0.559
Type of medication
Clozapine 6 7 6
Olanzapine 4 2 4
Risperidone 3 3 3
Aripiprazole 3 1 3
Quetiapine 2 3 1
Sulpiride – – 1
Haloperidol – – 3
Other first generation 1 3 4
None 1 – 1
Motor threshold Mean (+/2 SD) 60.2 (7.4) 56.7 (9.5) – 0.366
AHRS frequency item Mean (+/2 SD) 6.9 (2.8) 5.9 (2.7) 5.9 (3.0) 0.521
AHRS total Mean (+/2 SD) 28.3 (5.7) 25.6 (6.7) 24.8 (6.0) 0.241
PANSS P3 (Hallucinations) Mean (+/2 SD) 5.2 (0.7) 4.6 (0.6) 4.7 (0.7) 0.036
PANSS Positive Mean (+/2 SD) 16.3 (4.8) 15.8 (3.9) 16.7 (4.6) 0.856
PANSS Negative Mean (+/2 SD) 15.1 (4.7) 13.7 (4.7) 16.6 (5.6) 0.269
PANSS General
Psychopathology Mean (+/2 SD) 30.1 (8.9) 27.7 (6.2) 32.4 (9.5) 0.300
M = male; F = female; AHRS = Auditory Hallucinations Rating Scale [20]; PANSS = Positive and Negative Syndrome Scale [24]; PANAS = Positive and Negative Affect Scale
[50]. Groups were compared using analysis of variance (ANOVA), followed by Bonferroni’s post-hoc tests in case of significant effects. The chi square test was applied to
test group differences on the nominal variable sex.
doi:10.1371/journal.pone.0108828.t001
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General Psychopathology. Characteristics of the AVH were
measured with the Auditory Hallucinations Rating Scale (AHRS),
which is a self-report questionnaire [15]. It comprises seven items
(frequency, reality, loudness, number of voices, length, attentional
salience, distress level). AHRS frequency scores and total AHRS
scores were used for the analysis. Positive and negative emotional
affective states were measured with the Positive and Negative
Affect Scale (PANAS) [50] adapted for hallucinations (note that
this is a different scale than the PANSS). Participants were
instructed to indicate to what extent they experienced ten positive
and ten negative affective states during AVH. Items had to be
rated on a five-point scale, ranging from 1 = very slightly to
5 = extremely. Sum scores of all positive and all negative items
were calculated and used for analysis. Both the AHRS and
PANAS were administered before and immediately after treat-
ment. For the measurements at four weeks and three months
follow-up we sent the questionnaires by mail to the participants.
fMRI procedure
In 36 participants, fMRI scans were made before and after
rTMS treatment, the results of the fMRI analyses are discussed
elsewhere [51].
Statistics
Differences in demographic characteristics and baseline data
between the three treatment groups were tested with analysis of
variance (ANOVA), followed by Bonferroni’s post-hoc tests in case
Figure 1. Flow diagram demonstrating the progress of the trial.
doi:10.1371/journal.pone.0108828.g001
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of significant effects. Chi-square tests were applied to the nominal
variables.
The influence of patients, time, and treatment on the outcome
measures of the PANSS (Hallucination item P3, Positive
symptoms, Negative symptoms and General Psychopathology),
AHRS (Frequency and Total) and PANAS (Positive and Negative)
were analyzed using multilevel modeling, because this technique
handles missing data better than single level designs. It does not
require balanced designs (e.g. same sample sizes in each level of
the design) and is more flexible.
A two-level random intercept model was fitted to the data.
Repeated measurements in Time (for the PANSS: baseline and
end of treatment; for the AHRS and PANAS: baseline, end of
treatment, four weeks follow-up and three months follow-up) were
nested within patients. Group (left rTMS, bilateral rTMS and
sham rTMS) was added as a covariate. The main effects of Time
and Group are given, as well as their interactions. In case of
significant main or interaction effects, estimates of fixed effects are
presented, to clarify which differences caused the effects. P-values
of ,.05 were considered statistically significant. We used the IBM




The flow diagram (Figure 1) demonstrates the progress of the
trial. 68 patients were assessed for eligibility, and eventually 51
patients were included in the trial. A total of four patients
withdrew from the study, for various reasons, which are described
in the safety and tolerability section. So, 47 participants completed
the study, with 16 patients in the left group, 15 patients in the
bilateral group, and 16 patients in the sham group. Demographic
characteristics did not differ significantly between the three
treatment groups (Table 1). There were no baseline differences
between groups in hallucination severity as reflected by the
AHRS. Baseline scores on hallucination item P3 of the PANSS
were not equal between the three groups; however post-hoc testing
revealed no significant differences between the groups (Table 1).
Short term-efficacy measured with the PANSS P3 item
and subscales
Mean scores on the PANSS are displayed in Table 2. There was
no significant main effect of group on the PANSS Hallucination
item P3 (F(2,44.0) = 1.034, p = 0.364). However, the main effect of
time (pre- vs. post-treatment) was significant (F(1,44.0) = 5.942,
p = 0.019). The interaction between time and treatment group
showed a trend for significance (F(2,44.0) = 2.545, p = 0.090),
which was caused by a small decrease of hallucination severity in
the left treatment group. Figure 2 illustrates the individual courses
in hallucination scores. Each line represents how many subjects
showed a specific change in hallucination score, separate for the
three treatment groups.
Treatment group or time did not have significant effects on the
total positive symptoms, negative symptoms and general psycho-
pathology subscales.
Short term and long term efficacy, as measured with the
AHRS
Mean scores on the AHRS are displayed in Figure 3 and
Table 2. Analysis revealed a significant main effect of the factor
time for the AHRS Frequency scores (F(3,41.6) = 4.92, p = 0.005).
Table 3 summarizes the results of pairwise comparisons and shows
that the means on all post treatment measurements decreased
significantly compared to baseline. So AHRS frequency scores
were significantly lower at the end of treatment, when compared
to the measurement at baseline and remained on a lower level for
at least three months (Table 3). The reduction of AHRS frequency
scores over time was independent of the treatment condition, as
there was no main effect of treatment, or interaction between time
and treatment.
Total AHRS scores also decreased over time (F(3,40.9) = 2.89,
p = 0.047). However, pairwise comparisons only showed trends for
significance between the mean at baseline and the means at four
weeks follow-up and three months follow-up (Table 3). Again,
main effects of treatment and the interaction between treatment
and time were not significant.
Short term and long term efficacy, as measured with the
PANAS
Mean scores on the PANAS are displayed in Table 2. Both
negative and positive affect scores as measured with the PANAS
showed significant decreases in time (F(3,38.0) = 5.69, p = 0.003;
F(3,40.5) = 6.29, p,0.001, respectively). In case of the PANAS
negative scores, this effect was caused by significant decreases after
four weeks follow-up compared to baseline, and remained
decreased until three months follow-up. The PANAS positive
scores decreased during the treatment and stayed on a constant
level for three months (Table 3). There were no main effects for
treatment or interaction effects on either PANAS positive or
negative scores.
Responder analysis
Eight patients in the left group improved one point or more on
the PANSS Hallucination item P3, against five patients in the
bilateral group and four in the sham group. In five patients from
the sham group, the scores increased one point, against one patient
in the bilateral group and none in the left group.
When considering a reduction of three points or more on the
AHRS frequency item as a response, five patients in the left group
were responders, and one patient in the bilateral group, against
three in the sham group.
Blinding
Not all data on blinding success were available. Out of the
sixteen participants surveyed in the left group, ten thought they
received real treatment (62.5%), in the bilateral group nine out of
twelve surveyed thought they received real treatment (75%),
against ten out of sixteen patients surveyed in the sham group that
believed they received sham rTMS (62.5%).
TMS safety and tolerability
Four patients withdrew from the study, for the following
reasons: increase of psychotic symptoms; severe back pain that the
patient attributed to the rTMS treatment; and inability to visit the
hospital due to illness.
In the patients that completed the treatment, rTMS was well
tolerated and no serious adverse events occurred. Side-effects
reported in the active rTMS groups were: twitching facial muscles
(ten patients), light-headedness (one patient), earache (one patient),
tingling sensation in the arm on the contralateral side of rTMS
stimulation, and minor pain in the left arm (one patient). These
side-effects were confined to the actual stimulation session, and
disappeared immediately after stimulation. One patient that
received active rTMS experienced restless legs during stimulation,
but she already had these complaints before participating in the
trial. Nine participants in the active groups and two in the sham
Left and Bilateral rTMS for Auditory Hallucinations
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e108828
group reported mild transient headache following (at least one)
stimulation session. Other side-effects reported in the sham group
were a tingling sensation near the ear (one patient) and blunted
affect (one patient) during the stimulation session. One patient in
the sham group reported concentration problems during the
treatment period.
Discussion
In this trial we randomized 51 schizophrenia patients with
treatment resistant auditory verbal hallucinations to receive 1 Hz
rTMS treatment of the left or bilateral TPJ area, or sham rTMS.
The present study was conducted as an extension of the RCT
reported by Vercammen et al. [44] on 36 patients. This is the first
study on hallucinations that included an extra treatment arm of
bilateral stimulation to allow for the comparison of different
treatment configurations. We hypothesized that stimulation of the
left TPJ area would result in decreased frequency, loudness or
attentional salience of AVH through diminution of left-hemi-
spheric hyperactivation, and that bilateral stimulation would
additionally reduce affect-based aspects of AVH thought to
originate in the right hemisphere. This would theoretically result
in a more complete management of AVH. We observed a
significant decrease in mean hallucination score that remained
stable for three months. Although left-sided rTMS showed a trend
to significance on the PANSS, neither left nor bilateral rTMS
treatment was superior over sham treatment in reducing
hallucination severity as measured with the AHRS and PANAS.
As the durability of rTMS effects is of specific interest to
clinicians, we included two follow-up measurements with the
AHRS and PANAS, at four weeks and three months. At each time
point a reduction of AVH was found, but it was irrespective of
treatment condition. This corroborates findings of other studies
that included long-term follow-up assessments [20,24,28]. It is
remarkable that hallucination severity tends to decrease over time
in a relatively stable and chronically ill sample, both after active
and sham treatment. It is conceivable that participating in an
rTMS trial to reduce auditory verbal hallucinations, promotes
awareness and a realization that AVH are a product of ‘abnormal’
neural processes, residing in the brain, rather than originating
from some external source. From this point of view, it may become
easier for patients to cope with their hallucinations and/or they
may even find a way to influence them.
By stimulating bilaterally, we applied an unconventional
approach in the study of rTMS for AVH. Three previous studies
compared the effects of right-sided rTMS with left-sided rTMS
and sham stimulation, but did not observe superior effects of right-
sided stimulation [21,25,26]. Contrary to our study, the rationale
for adding a third treatment arm of right-sided rTMS in these
former studies was not specifically based on the hypothesis that the
right hemisphere might influence the emotional states accompa-
nied with the AVH. We assessed positive and negative emotional
states associated with the experience of hallucinations, observing
an overall decrease in the scores of both positive and negative
emotional states during the study period in all three treatment
groups. Thus, our hypothesis that low-frequency bilateral stimu-
lation specifically would result in more complete management of
AVH could not be confirmed. The possibility should be
considered that the lack of beneficial effects of bilateral stimulation
is due to a neurophysiological process referred to as transcallosal
inhibition. Thiel et al. [52] have shown that low frequency rTMS
of the left inferior frontal gyrus resulted in increased activity in the
right inferior frontal gyrus. In our design, inhibition of the left TPJ
area might have caused disinhibition of its corresponding
contralateral area, and vice versa, which may have produced a
null-effect. Theoretically, low frequency rTMS of the left TPJ
area, combined with high frequency rTMS of the right TPJ area,
may induce a stronger effect. As various bilateral approaches are
possible, further exploratory work will be necessary to clarify
which configuration would be most advantageous in the treatment
of hallucinations. Another explanation for the lack of improve-
ment in the bilateral condition may be that each hemisphere
received 50% fewer rTMS pulses than in the left rTMS condition,
such that the total amount of pulses applied to participants was
equal in every treatment condition. Perhaps 20 minutes of 1 Hz
rTMS on each side, might have achieved a significant treatment
effect.
Nevertheless, as we did not observe improvement in either of
the active rTMS conditions, it may be more plausible that the
overall lack of substantial, clinically relevant improvements can be
ascribed to methodological variables. Increasing stimulation
intensity, varying frequency, and extending duration of treatment
may positively influence efficacy. For instance, a two-day high-
frequency treatment has demonstrated remarkable efficacy in two
studies [47,53]. Moreover, it is still debatable whether the left TPJ
area – which is assumed to be hyperactive – should be stimulated
in isolation. Recent imaging findings revealed reduced connectiv-
ity and information flow between left frontal and temporal areas in
schizophrenia patients with AVH [54–56]. Additionally, hypo-
frontality has been reported in schizophrenia patients [57,58].
Taking this into account, high-frequency rTMS over the left
frontal area combined with low-frequency rTMS over the left TPJ
area, may strengthen fronto-temporal pathways, potentially
resulting in a more efficacious reduction of hallucination severity.
To our knowledge, this type of stimulation has not been performed
yet with rTMS. However, Brunelin et al. [59] obtained interesting
results using transcranial Direct Current Stimulation (tDCS). With
tDCS, cathodal and anodal electrodes are applied, which
respectively result in decreased or increased membrane potentials
of neurons underlying the respective stimulation sites. Cathodal
Figure 2. Changes in PANSS hallucination scores. This figure illustrates the individual courses in hallucinations score. Each line represents how
many subjects showed a specific change in hallucination score, separate for the three treatment groups.
doi:10.1371/journal.pone.0108828.g002
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left TPJ area stimulation to decrease underlying tissue activity and
anodal left dorsolateral prefrontal stimulation to elicit an increase
in activity resulted in a substantial decrease in AVH after 5 days.
In addition, this improvement sustained for at least three months
in the treatment group, whereas the sham group did not show
significant improvement. It goes without saying that replication
studies are required to substantiate this initial finding [60].
Aside from variability in stimulation parameters, variability
between subjects in response to rTMS treatment should also be
taken into account. Although not clinically significant, responder
analysis demonstrated that in the left rTMS group, twice as many
patients improved at least one point on the PANSS hallucination
item compared to the sham group. This finding might suggest that
left-sided rTMS does have some effect on AVH. It is conceivable
that the stimulation parameters were not optimally matched to the
individuals to elicit statistically and clinically relevant reductions of
AVH. This is in accordance with the increasing support for the
approach of personalized medicine in the treatment of schizo-
phrenia. Examining individual differences could expose factors
contributing to response. Accordingly, variability in brain struc-
ture, such as size, lateralization and gyrification might lead to
unreliable estimations of the localization of the TPJ area. Although
the International 10–20 EEG system we used for localization does
take variability in head size into account, it is difficult to account
for differences in brain morphology. Frameless stereotactic
neuronavigation using anatomical MRI scans may allow for more
accurate individual targeting. Few rTMS trials for the treatment of
AVH applied this method of localization, with mixed results
[25,30,31].
Not only brain structure, but also patterns of associated brain
activation during AVH may differ between patients [61,62]. One
study that used fMRI-guided rTMS, based on individually defined
areas of maximal activation during AVH, did not reveal additional
benefits [28]. Homan et al. [63] on the other hand, assessed
resting state perfusion in patients prior to treatment with rTMS.
Those patients who eventually responded to rTMS treatment were
Figure 3. Changes in AHRS Frequency scores. The three lines represent the mean AHRS Frequency scores for each treatment group during the
four measurements at baseline, end of treatment, and at four weeks and three months follow-up.
doi:10.1371/journal.pone.0108828.g003
Table 3. Pairwise comparisons between post-treatment measurements and baseline.
AHRS Frequency AHRS Total PANAS Positive PANAS Negative
Mean difference Mean difference Mean difference Mean difference
End of Treatment - Baseline 1.08** 2.55 4.57** 1.85
4 weeks follow-up - Baseline 1.26** 3.35* 4.77** 3.63**
3 months follow-up - Baseline 1.31** 3.03* 4.04** 3.61**
**significant at p#0.05. *trend for significance: 0.01,p,0.05. AHRS = Auditory Hallucinations Rating Scale [20]; PANSS = Positive and Negative Syndrome Scale [24];
PANAS = Positive and Negative Affect Scale [50].
doi:10.1371/journal.pone.0108828.t003
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characterized by increased cerebral blood flow in the left STG,
suggesting that resting-state activity of STG could serve as a bio-
marker of treatment response in schizophrenia patients with AVH.
In a PET study by Klı́rová et al. [29], resting regional brain
metabolism has been used for stereotactic neuronavigation to
determine the optimum area for stimulation, and found this
method to be superior over the traditional method and sham
stimulation. Albeit it requires further clarification, assessment of
functional brain activity before treatment may be valuable in the
prediction of treatment success.
Functional neuroimaging studies can also provide information
about the effect of rTMS on the underlying neural basis of AVH.
However, only few studies have assessed brain activation before
and after treatment. In a subgroup of present study sample, resting
state connectivity was investigated. Reduction in hallucinations in
the active rTMS group was correlated with an increased
connectivity between the left TPJ area and the right insula [51].
Kindler et al. [36] assessed patients with AVH before and after
treatment. The active treatment group showed both clinical
improvement and decreased blood flow in the primary auditory
cortex, left Broca’s area and the cingulate gyrus, whereas no
changes in activity occurred in the sham group. So indeed, the left
TPJ area appears an accurate target for influencing brain activity
within the AVH network. One study that investigated the effect of
rTMS on Broca’s area did not observe changes on a clinical or
neural level [64]. This supports the idea that the speech perception
areas in the temporal cortex, rather than speech production areas
in the frontal cortex are important for the experience of AVH
[65].
Since many of the rTMS studies in patients with AVH are
characterized by small sample sizes, we recommend the initiation
of large multi-center trials, and the validation of practical and
reliable clinical measures in order to enhance power and draw
stronger conclusions about the utility of rTMS in reducing AVH.
To improve blinding, studies should employ sham coils that mimic
the scalp sensation produced by real rTMS.
To summarize, although we observed a trend for AVH
reduction in the left rTMS group as measured by clinicians, this
improvement was not confirmed with self-reported hallucination
scores. We thus conclude that we did not find evidence for the
efficacy of left-sided rTMS, compared to sham stimulation.
Moreover, bilateral rTMS was not superior over left-sided rTMS
or sham in improving AVH. Mean self-reported hallucination
scores, and negative and positive emotional content as measured
with AHRS and PANAS were reduced during rTMS treatment
and over the course of a three-month follow-up period, but its
overall effect did not seem to be specific to either rTMS of the left
or bilateral TPJ area, or sham treatment. Optimizing treatment
parameters may yield more convincing evidence for efficacy of
rTMS treatment of AVH. Moreover, for future studies it is
recommended to incorporate evaluation of treatment effects with
neuroimaging. And in order to develop individually tailored
treatments, studies should focus on individual differences that may
influence treatment response.
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